DisclosureWe earn commission on partner links; ranking is set by clinician-vetted methodology — not advertisers.
Yes, based on 5-year SELECT cardiovascular outcomes trial data. Long-term risks include pancreatitis, gallstones, and thyroid C-cell tumors (rare, FDA boxed warning).
Wegovy long-term safety is supported by the SELECT trial — 17,604 patients followed for ~5 years showed cardiovascular benefit with manageable safety profile. Known long-term concerns: (1) Pancreatitis — rare but documented; discontinue if severe abdominal pain develops; (2) Gallstones and gallbladder disease — higher risk with rapid weight loss; (3) Thyroid C-cell tumors — FDA boxed warning based on rodent studies, no clear human signal; contraindicated if personal/family history of medullary thyroid carcinoma; (4) Diabetic retinopathy worsening in T2D patients — monitor; (5) Renal injury secondary to severe vomiting/dehydration. Bone density loss with prolonged use is an emerging research area. Lean muscle mass loss without exercise is well-documented. Annual physical with lab work is recommended for long-term users.
Editorial answer reviewed by a board-certified clinician. Not medical advice. Coordinate treatment decisions with your prescriber.